Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions
NCT ID: NCT01716013
Last Updated: 2017-01-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
162 participants
INTERVENTIONAL
2012-09-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To demonstrate safety of BondEase™.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Closure Techniques and Scar Appearance
NCT01352533
Skin Closures at Cesarean Delivery, Glue vs Subcuticular Sutures.
NCT04371549
Cosmetic Results With Tissue Adhesive vs. Subdermal Sutures in Cesarean Section
NCT06760026
LiquiBand Versus Dermabond Versus Sutures for Closure of Surgical Wounds
NCT01835405
Effect of Replacing Buried Sutures With Tissue Adhesive on Aesthetic Outcome of Surgical Wounds.
NCT03425370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Part 1 of the study 30 subjects will be randomized in a 2:1 ratio (BondEase™ : CWCD). This part of the study is designed to assess the feasibility and validate use of the device. Pediatric subjects younger than age 18 will not be included in this part of the trial. The results from these 30 subjects will be compiled and submitted to FDA for review and approval prior to proceeding with Part 2. Part 2 of the study will only be initiated after FDA indicates it is acceptable to begin. In Part 2 of the study a total of 123 subjects will be randomized, of which 82 subjects will be randomized to the BondEase™ group and 41 subjects to the CWCD group. This will result in 102 subjects in the BondEase™ group and 51 subjects in the CWCD group across the both parts of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BondEase
Topical Skin Adhesive
BondEase
topical skin adhesive
CWCD
Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
CWCD
traditional closure methods of sutures, staples or adhesive strips
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BondEase
topical skin adhesive
CWCD
traditional closure methods of sutures, staples or adhesive strips
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has a wound requiring surgical repair, where the use of a tissue adhesive is appropriate
3. Is in good general health
4. Subject or the guardian understands and is willing to sign informed consent prior to study entry and agrees to be available for the Day 10, Day 28, and Day 90 (Part 1/pilot phase only) follow-up visits
Exclusion Criteria
2. Known peripheral vascular disease
3. Known diabetes mellitus type 1 or type 2
4. Known blood clotting disorder
5. Patient or family history of keloid formation or hypertrophy
6. Known HIV seropositivity or is immunocompromised
7. Been treated with an investigational drug or medical device in the past 30 days
8. A hypersensitivity or contraindication to any of the components of BondEase™
9. Known pre-operative systemic or local infection
10. Any other diseases or conditions which might interfere with the wound healing process
11. The wound to be treated with the test device may not have any of the following characteristics:
* A "burst" or stellate laceration
* Heavily contaminated (Contaminated Wound: wounds that are grossly contaminated with foreign material requiring extensive cleansing.
* Human or animal bite
* Decubitus etiology
* Evidence of active infection or gangrene
* On mucosal surfaces or across mucocutaneous junctions (e.g., oral cavity, lips)
* On an area which may be regularly exposed to body fluids or with dense natural hair, (e.g., scalp)
* Under tension or over a joint
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OptMed, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orlando Regional Medical Center
Orlando, Florida, United States
Northwestern University
Chicago, Illinois, United States
DC Cosmetics
Chevy Chase, Maryland, United States
Albany Medical Center
Albany, New York, United States
Sadick Research Group
New York, New York, United States
Wake Forest Baptist Health
Wake Forest, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PD-100-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.